Twitter Beğeni Hilesi

Thank you Sumanta K. Pal, MD, FASCO for this succinct and necessary analysis of the state of standard of care treatment for #nonclear and #papillary #kidneycancer. Thanks also for highlighting our trial finder tool. Critical for any patient, esp those still not well advised about them. #ESMO24

So proud of Regina Barragan-Carrillo Miguel Zugman & Hedyeh Ebrahimi - my current City of Hope fellows - who knocked it out of the park at the ESMO - Eur. Oncology GU poster session! Terrific work spanning #kidneycancer, #bladdercancer & #testicularcancer (the latter mentored by Alex Chehrazi-Raffle, MD). #ESMO24

Terrific discussion by Bogdana Schmidt MD, MPH reviewing the role of biomarkers and ways to optimize outcomes in the perioperative setting in patients with #bladdercancer at #ESMO24 ESMO - Eur. Oncology Neeraj Agarwal, MD, FASCO Huntsman Cancer Institute GU Cancer Research Program @HuntsmanCancer Neli Ulrich, PhD Bladder Cancer Advocacy Network UroToday.com OncoAlert

Intra-vesical TAR-200 + cetrelimab (CET) vs CET as neoadjuvant Rx in pts with MIBC #bladdercancer (ineligible or refusing neoadjuvant cisplatin👉Interim analysis of SunRISe-4👉Stellar talk by the master Andrea Necchi ESMO - Eur. Oncology #ESMO24 👉42% pCR with combo👇Sarah P. Psutka MD MS OncoAlert

Nivolumab + chemoradiotherapy in pts with MIBC #bladdercancer not undergoing cystectomy👉A phase II, randomized study by the Hellenic GU Cancer Group👉encouraging improvement in disease free- and overall survival. ESMO - Eur. Oncology #ESMO24 Congrats! OncoAlert UroToday.com Hellenic Oncological Society of Diaspora-HeL.O.DI

Terrific talk and perspective on the ESMO - Eur. Oncology #ESMO24 #bladdercancer abstracts by Shilpa Gupta Cleveland Clinic 👉 Tremendous advancements in systemic Rx will allow many pts to preserve bladder in the near future, need modern tools to measure PROs. Congrats! OncoAlert UroToday.com

Outstanding discussion by Shilpa Gupta putting into context the results of nivo + chemoradiotherapy in NMIBC and HRQoL results from CheckMate 901 w/ nivo+ gem-cis in mUC #bladdercancer #ESMO24 ESMO - Eur. Oncology 👇🏻 Neeraj Agarwal, MD, FASCO UroToday.com OncoAlert Bladder Cancer Advocacy Network

Efficacy and safety of darolutamide + ADT vs ADT in pts in mHSPC #ProstateCancer from the phase 3 ARANOTE trial ESMO - Eur. Oncology #ESMO24 by • 👉rPFS, the primary endpoint met (HR:0.54), PSA<0.2 ng/ml anytime occurred in 62%. PCF Science UroToday.com OncoAlert

Prof Ruth Langley w drug repurposing — Can transdermal estrogen replace androgen suppression in #prostatecancer? Similar efficacy, yet w improved hot flashes, less bone density loss. Congrats to the UK team! ESMO - Eur. Oncology #ESMO24 #ESMOAmbassadors ESMO - Eur. Oncology

Beautiful talk by Chad Tang, MD MD Anderson Cancer Center at #ESMO24 (in session led by Cris) discussing the (1) complicated hx of XRT in RCC (weak preclinical data, poorly designed “adjuvant” trials, (2) current rationale for using #SBRT (or surgery!) for #oligometastatic dz (incl

No Overall survival benefits of adding metformin to ADT systemic therapy in patients with mHSPC #ProstateCancer in the STAMPEDE trial👉excellent talk by silke gillessen at #ESMO24 ESMO - Eur. Oncology 👇Conclusions👇 UroToday.com PCF Science OncoAlert Cancer Research UK

Fantastic & thoughtful discussion by Shilpa Gupta on the Hellenic group phase 2 trial on chemoRT +/- nivolumab & qOL/PRO data from CM901! OncoAlert UroToday.com ESMO - Eur. Oncology #ESMO24 #ESMOambassadors Uromigos Tom Powles Andrea Apolo, M.D. Sumanta K. Pal, MD, FASCO Neeraj Agarwal, MD, FASCO Tian Zhang, MD, MHS Dr. Bishoy M. Faltas

🤤 I have no words 😶. Can’t be more proud!!! A rising new star 💫 Teresa Alonso Gordoa has done one of the most comprehensive reviews on the systemic management of mRCC at #ESMO24. Huge kudos to!!!👏👏👏🙌🏻 OncoAlert GUARD Consortium ESMO - Eur. Oncology

Terrific talk by Deborah Mukherji on the ESMO - Eur. Oncology #ESMO24 #ProstateCancer data👉Radio pharmaceutical are SOC, optimize QOL with sequencing of Rx, more data on metformin needed. PCF Science UroToday.com OncoAlert

Great talk from Teresa Alonso Gordoa at #ESMO24 on systemic therapy for #kidneycancer key points around toxicity (see comparison across pivotal 1L studies below), innovative studies investigating novel schedules (eg TIDE-A by Roberto Iacovelli, now in European Urology), 2L therapy (w up-to-date

Efficacy and safety of BMS-986365, a dual AR ligand-directed degrader, in pretreated pts with mCRPC #ProstateCancer by Dana Rathkopf in #ESMO24 ESMO - Eur. Oncology 👉PSA response and rPFS by AR LBD mutation status👇QTc prolongation, the most common TRAE. Andrew Armstrong UroToday.com OncoAlert

Fantastic to have a joint session between ESMO - Eur. Oncology ASCO the vision is phenomenal led by brilliant leaders from both organizations! Julie Gralow Robin Zon, MD, FACP, FASCO Andres Cervantes Solange Peters G Curigliano MD PhD FabriceAndre Clifford Hudis George Pentheroudakis Vivek Subbiah, MD OncoAlert Dr. Tom Lynch

⭐️Great GU sessions at #ESMO24. Love catching up with friends and listening to their stellar research presentations David Braun Vadim Koshkin MD Tanya Jindal Sumanta K. Pal, MD, FASCO ESMO - Eur. Oncology

Nearly 1/2 of National Cancer Institute treatment trial participants reported ever smoking, & 1 in 6 were current or recent people who smoked, w/ higher rates among vulnerable populations. Routine tobacco assessments may help reduce cancer disparities. acsjournals.onlinelibrary.wiley.com/doi/full/10.10… OncoAlert #ESMO24

‼️Next conference: ASCO #ASCOQLTY24 in San Francisco, Sep 27-28! I'm honored to serve on the Program Committee for this incredible event. If you haven’t registered yet, don’t miss this opportunity: conferences.asco.org/quality/attend Raymond Osarogiagbon, MBBS, FACP Fumiko Ladd Chino, MD, FASCO Cardinale B. Smith